Edgewise Therapeutics Reaches New 12-Month High

Shares of the biopharmaceutical company hit a new 52-week high amid analyst optimism.

Apr. 20, 2026 at 3:09pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, interlocking metal gears and mechanisms, conveying the complex, powerful machinery of the financial industry as a conceptual metaphor.Edgewise Therapeutics' stock surge reflects growing investor confidence in the company's pipeline of rare disease treatments, particularly its lead kidney disorder drug candidate.Cambridge Today

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on rare diseases, saw its stock price reach a new 52-week high on Monday. The company's shares traded as high as $35.00 and closed at $34.0290, with heavy trading volume of over 823,000 shares.

Why it matters

Edgewise Therapeutics' stock price surge reflects growing investor confidence in the company's pipeline of precision medicines, particularly its lead candidate EWTX-101, a novel inhibitor of the TRPC5 calcium channel that is being developed for the treatment of kidney disorders such as focal segmental glomerulosclerosis (FSGS). The new 52-week high suggests the market is optimistic about Edgewise's potential to address severe, unmet medical needs in rare diseases.

The details

The stock's rise follows a series of positive analyst reports. JPMorgan Chase & Co. raised its price target on Edgewise Therapeutics from $34.00 to $45.00 and maintained an 'overweight' rating, while Wedbush reiterated an 'outperform' rating and $32.00 price target. However, Wall Street Zen downgraded the stock from 'hold' to 'sell'.

  • Edgewise Therapeutics' stock hit a new 52-week high on Monday, April 20, 2026.
  • The company reported its latest quarterly earnings on Thursday, February 26, 2026.

The players

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases.

JPMorgan Chase & Co.

A multinational investment bank and financial services company that raised its price target on Edgewise Therapeutics.

Wedbush

An investment firm that reiterated an 'outperform' rating and $32.00 price target on Edgewise Therapeutics.

Wall Street Zen

An investment research firm that downgraded Edgewise Therapeutics from 'hold' to 'sell'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.